Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRKCQ antisense RNA 1 (PRKCQ-AS1)
- Target
- PRKCQ-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Non-coding regulatory RNA
01
Overview
PRKCQ antisense RNA 1 (PRKCQ-AS1) is a long noncoding RNA primarily expressed in the cytoplasm and implicated in cancer and immune regulation. In colorectal cancer, PRKCQ-AS1 facilitates tumor progression by acting as a competing endogenous RNA for miR‑1287‑5p, leading to upregulation of the oncogene YBX1 and enhanced proliferation and migration of cancer cells[1]. In papillary thyroid carcinoma and under fasting conditions, PRKCQ-AS1 regulates glycolysis and mitochondrial function through interaction with IGF2BPs and PRMT7, inhibiting tumor growth[2]. PRKCQ-AS1 also functions in immune response and inflammation—shown to promote apoptosis, inflammatory damage and oxidative stress in sepsis models, and to correlate with patient prognosis[3]. Its expression is used as a biomarker for disease progression in cancer and sepsis. While no clinical drugs target PRKCQ-AS1 yet, it represents a potential therapeutic target for RNA-based therapies in oncology and immunology[1][2][3][4][5].
- Other names
- PRKCQ-AS1Ensembl: ENST00000414894.1HGNC: 44689NCBI Gene: 439949ENSG00000237943
02
Mechanism of action
Antisense or RNA interference drugs would act by suppressing PRKCQ-AS1 expression, thereby restoring tumor suppressor miR-1287-5p function, reducing YBX1 oncogene expression, or altering PRMT7-mediated metabolic signaling
03
Biological functions
Regulation of cell proliferation and migration (via miR-1287-5p/YBX1 axis and IGF2BPs/PRMT7 signaling)Immune response regulation, including T cell activation and inflammationCell cycle modulation and apoptosis inductionRegulation of glycolysis and mitochondrial function
04
Disease associations
Cancer (colorectal cancer, papillary thyroid carcinoma, triple-negative breast cancer)Sepsis (immune and prognostic marker)Inflammation
05
Safety considerations
As a noncoding RNA, direct targeting might present challenges including off-target effects, delivery specificity, and risk of impacting broad regulatory networks.No specific adverse events or toxicities are reported for agents targeting PRKCQ-AS1, as none are clinically used yet.
06
Biomarkers
PRKCQ-AS1 expression level as a biomarker for prognosis in sepsis and several cancersDownstream markers: miR-1287-5p, YBX1, PRMT7, Ki-67 staining for proliferation, glycolytic enzymes (PDK1, LDHA, HK2, GLUT1, GPI)
Beyond the preview
Go deeper on PRKCQ antisense RNA 1 (PRKCQ-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRKCQ antisense RNA 1 (PRKCQ-AS1).